Log In
BCIQ
Print this Print this
 

INO-8000, VGX-6150

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynCon DNA vaccine covering HCV genotype 1
Molecular Target HCV NS3/4A protease complex ; HCV NS4B transmembrane protein
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotypes 1a and 1b infection
Regulatory Designation
PartnerGeneOne Life Science Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/17/2011

Undisclosed

0

Undisclosed

Get a free BioCentury trial today